| ABI3 | |
|---|---|
| Full Name | ABI Family Member 3 (Abl Interactor 3) |
| Gene Symbol | ABI3 |
| Chromosomal Location | 17q21.31 |
| NCBI Gene ID | 10027 |
| OMIM | 609469 |
| Ensembl ID | ENSG00000108506 |
| UniProt ID | Q9NZU7 |
| Protein Length | 360 amino acids |
| Category | Immune/Microglial/Cytoskeletal |
ABI3 (ABI Family Member 3), also known as NESH or SH3D5, is a gene located on chromosome 17q21.31 that encodes a member of the Abl-interactor (ABI) protein family. ABI3 was identified as a significant risk gene for Alzheimer's disease (AD) through large-scale genome-wide association studies (GWAS), implicating microglial dysfunction in AD pathogenesis [1].
ABI3 plays crucial roles in actin cytoskeleton regulation through its interaction with the WAVE regulatory complex (WRC), which controls actin polymerization and is essential for microglial phagocytosis, migration, and morphological changes. The discovery of ABI3 as an AD risk gene highlighted the importance of microglial cytoskeletal dynamics in neurodegeneration.
ABI3 is a relatively small protein (360 amino acids) with a modular domain architecture:
| Domain | Location | Function |
|---|---|---|
| SH3 Domain | C-terminal | Protein-protein interactions, binds proline-rich motifs |
| WHD (WAVE Homology Domain) | Central | Mediates WRC complex formation |
| Proline-rich Region | N-terminal | Contains PXXP motifs for SH3 interactions |
| Basic Region | N-terminal | Potential DNA/RNA binding |
SH3 Domain: Located at the C-terminus, mediates interactions with proline-rich motifs in target proteins including WAVE2, EPS8, and various signaling molecules.
WAVE Homology Domain (WHD): Shared among ABI family members, this domain is critical for assembling into the WAVE regulatory complex.
Proline-rich Region: Contains multiple PXXP motifs that serve as docking sites for SH3 domains from other proteins.
ABI3 is a core component of the WAVE regulatory complex (WRC), which controls actin cytoskeleton dynamics:
| Component | Function | Size |
|---|---|---|
| WAVE2 (WASF2) | Actin nucleation promoter | 527 aa |
| ABI3 | Scaffold and activator | 360 aa |
| BRK1 | Small subunit | 159 aa |
| NCKAP1L (PIR121) | Scaffold protein | 1,228 aa |
| CYFIP2 (SCAR) | F-actin binding | 1,254 aa |
The WRC exists in an autoinhibited state under basal conditions:
The WRC activates the Arp2/3 complex, which nucleates new actin branches from existing filaments:
Microglia depend on rapid cytoskeletal remodeling for their surveillance and response functions:
| Function | ABI3/WRC Role | AD Relevance |
|---|---|---|
| Cell morphology | Lamellipodia formation | Morphological changes in DAM |
| Chemotaxis | Directed migration | Plaque recruitment |
| Phagocytosis | Engulfment machinery | Aβ clearance |
| Process extension | Motile protrusions | Surveillance |
| Process retraction | Actin disassembly | Morphological plasticity |
ABI3-mediated actin remodeling is essential for microglial phagocytosis:
ABI3 plays a role in microglial activation states:
ABI3 was identified as an AD risk gene in a landmark 2017 study that also identified PLCG2 and TREM2 rare variants [1:1]:
| Study | Key Finding | Effect Size |
|---|---|---|
| Sims et al. 2017 | Rare variant identification | OR = 2.0-3.0 |
| Jansen et al. 2019 | GWAS meta-analysis | Confirmed |
| Kunkle et al. 2019 | Genetic meta-analysis | Confirmed |
Multiple ABI3 variants affect AD risk:
| Variant | Type | Population Frequency | Effect |
|---|---|---|---|
| rs2275544 | Intron | ~20% | Increased risk |
| rs616338 | Intron | ~15% | Increased risk |
| rs28394864 | Intron | ~10% | Increased risk |
| Loss-of-function | Coding | Rare | Increased risk |
The risk alleles are associated with:
ABI3 variants affect microglial function through multiple mechanisms:
Studies using ABI3-deficient mice demonstrate causality:
ABI3 works cooperatively with other microglial AD risk genes:
| Gene | Function | Interaction with ABI3 |
|---|---|---|
| TREM2 | Phagocytosis activation | Synergistic pathways |
| PLCG2 | Signaling modulation | Coordinated activation |
| CD33 | Phagocytosis inhibition | Opposing functions |
| APOE | Lipid transport | Complementary |
Given its role in microglial function, ABI3 represents a potential therapeutic target:
| Strategy | Approach | Status |
|---|---|---|
| Gene therapy | Deliver functional ABI3 | Preclinical |
| Small molecules | Modulate WRC activity | Discovery |
| Phagocytosis enhancement | Bypass impaired signaling | Research |
| Microglial modulation | Shift to protective phenotype | Research |
Several challenges face ABI3-targeted therapies:
ABI3 interacts with multiple proteins relevant to neurodegeneration:
| Interactor | Function | AD Relevance |
|---|---|---|
| WAVE2 (WASF2) | Core WRC component | Direct interaction |
| ABL1/ABL2 | Tyrosine kinases | Signaling |
| EPS8 | Growth factor signaling | Parallel pathways |
| Rac1 | GTPase regulation | Activation |
| TREM2 | Microglial receptor | Functional synergy |
| CD33 | Phagocytosis modulation | Coordinated |
| INPP5D (SHIP1) | Phosphatase signaling | Modulation |
ABI3 shows highest expression in:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Microglia | Very High | Primary CNS expression |
| Perivascular macrophages | High | Border-associated |
| Monocytes | High | Peripheral immune |
| Neurons | Very Low | Minimal |
| Astrocytes | Very Low | Minimal |
| Cell Type | Expression Level |
|---|---|
| Monocytes | High |
| Macrophages | High |
| Dendritic cells | Moderate |
| T cells | Low |
| B cells | Low |
| Gene | Primary Function | ABI3 Relationship |
|---|---|---|
| TREM2 | Phagocytosis activation | Synergistic |
| PLCG2 | Signaling | Coordinated |
| CD33 | Phagocytosis inhibition | Antagonistic |
| ABI3 | Cytoskeletal regulation | Primary |
Given its role in microglial function, ABI3 represents a potential therapeutic target for Alzheimer's disease:
| Strategy | Approach | Development Status |
|---|---|---|
| Gene therapy | Deliver functional ABI3 to microglia | Preclinical validation |
| Small molecule modulators | Enhance WRC activity | Discovery phase |
| Phagocytosis enhancement | Bypass impaired ABI3 signaling | Research stage |
| Microglial phenotype modulation | Shift toward protective DAM | Early investigation |
Several challenges face ABI3-targeted therapies:
ABI3 has potential as a disease biomarker:
ABI3 shows significant evolutionary conservation:
| Species | Ortholog | Sequence Identity |
|---|---|---|
| Human | ABI3 | 100% |
| Mouse | Abi3 | 94% |
| Rat | Abi3 | 93% |
| Zebrafish | abi3a | 72% |
| Drosophila | CG32666 | 58% |
The conservation of WRC components across eukaryotes highlights the fundamental importance of actin cytoskeleton regulation in cellular function.
Studies in model organisms reveal:
Last updated: 2026-03-25
Sims R, et al. Rare variants in PLCG2, ABI3, and TREM2 increase risk for AD. Nat Genet. 2017. ↩︎ ↩︎